A Randomized, Placebo-Controlled, Double-Blind Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of ITI-214 in Patients With Idiopathic Parkinson's Disease

Trial Profile

A Randomized, Placebo-Controlled, Double-Blind Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of ITI-214 in Patients With Idiopathic Parkinson's Disease

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Aug 2018

At a glance

  • Drugs ITI 214 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Sponsors Intra-Cellular Therapies
  • Most Recent Events

    • 25 Jul 2018 Planned number of patients changed from 32 to 40.
    • 25 Jul 2018 Planned primary completion date changed from 1 May 2018 to 1 Aug 2018.
    • 03 May 2018 According to the Intra-Cellular Therapies media release, top-line results from this trial will be available in 2H 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top